The usual answer is lion's mane for focus, reishi for calm, and that split is roughly right about intent and almost useless about evidence. Lion's mane has more human trials, but nearly all of them recruited people with existing cognitive impairment. Reishi's single best result is larger and better-powered than anything lion's mane has produced in healthy adults — and it is a fatigue result, not a sleep one. Meanwhile a safety difference between the two decides more real cases than either benefit claim.
Lion's mane: three relevant human trials. Mori 2009 gave 3 g a day to 30 adults aged 50–80 with mild cognitive impairment for 16 weeks, with significant gains at weeks 8, 12 and 16 that reversed four weeks after stopping. Li 2020 ran 49 weeks in mild Alzheimer's, where the significant decline occurred in the placebo arm. Docherty 2023 is the only healthy-adult trial: 41 people, 1.8 g, faster Stroop performance 60 minutes after a single dose (p = 0.005) and a stress reduction that missed significance after 28 days (p = 0.051), with null findings also reported. Reishi: Tang 2005 randomised 132 patients with neurasthenia to 5.4 g a day of a polysaccharide extract for eight weeks, cutting fatigue 28.3% from baseline against 20.1% on placebo, with 51.6% versus 24.6% rated more than minimally improved. Reishi's cardiovascular claims are Cochrane-null, and it has no human sleep RCT.
Both are reasonable purchases. They are reasonable for different reasons than the marketing gives, and one of them has a documented interaction the other does not.
What Lion's Mane Has Behind It
Three trials worth discussing, and the population matters more than the count.
Mori's 2009 study is the foundational one: 30 Japanese adults aged 50 to 80 with diagnosed mild cognitive impairment, randomised into two arms of fifteen, taking 3 grams a day of dried powder for 16 weeks. Cognitive scores rose significantly against placebo at weeks 8, 12 and 16, increasing with duration — then fell significantly four weeks after intake stopped.
Li's 2020 trial ran 49 weeks of erinacine A-enriched mycelium in mild Alzheimer's disease. Reading the results carefully, a significant cognitive decline appeared in the placebo group while the treatment group improved on the Mini-Mental State Examination and held instrumental daily function. That is prevented deterioration more than enhancement, as our Alzheimer's article sets out.
Docherty's 2023 pilot is the only one that recruited healthy young adults — 41 people aged 18 to 45, 1.8 g, double-blind and placebo-controlled. Sixty minutes after a single dose, participants performed faster on the Stroop task (p = 0.005). After 28 days, subjective stress trended down without reaching significance (p = 0.051). The authors also report null and limited negative findings, and flag the small sample.
Add Nagano's 2010 study, in which lion's mane baked into cookies for four weeks reduced depression and anxiety scores in women, and the picture is: real signals, small samples, mostly in impaired or symptomatic populations.
What Reishi Has Behind It
One substantially better-powered trial, and a set of claims that did not survive testing.
Tang's 2005 study randomised 132 patients diagnosed with neurasthenia — chronic fatigue and weakness — to a Ganoderma lucidum polysaccharide extract at 1,800 mg three times daily, or placebo, for eight weeks. Among 123 evaluable patients, sense of fatigue fell 28.3% from baseline against 20.1% on placebo, clinical global impression severity fell 15.5% against 4.9%, and sense of well-being rose 38.7% against 29.7%. Of the treatment group, 51.6% were rated more than minimally improved against 24.6% on placebo (p = .002).
That is 132 participants against lion's mane's 30 and 41, with a clinically legible endpoint.
What reishi does not have is equally important. The 2015 Cochrane review of reishi for cardiovascular risk factors pooled five trials and 398 participants and found no significant benefit on HbA1c, cholesterol, LDL or BMI. Chu's crossover trial in patients with borderline elevated blood pressure found no change in blood pressure. And despite being the default sleep mushroom, reishi has no published randomised sleep trial in humans — the sleep story is preclinical, as our reishi and sleep article explains.
The Comparison That Actually Matters
| Lion's mane | Reishi | |
|---|---|---|
| Best trial size | 41 healthy adults; 30 with impairment | 132 patients with neurasthenia |
| Population studied | Mostly cognitively impaired older adults | Symptomatic fatigue |
| Best-evidenced endpoint | Cognition in impairment; acute processing speed | Fatigue and global improvement |
| Trial dose | 3 g/day dried powder; 1.8 g acute | 5.4 g/day polysaccharide extract |
| Duration to effect | 8–16 weeks; acute effect at 60 minutes | 8 weeks |
| Persists after stopping? | No — gains reversed within 4 weeks | Not tested |
| Sleep evidence | Mood and anxiety signals only | None in humans |
| Platelet effect | None notable in eight-species screen | Exceeded aspirin on one test in vitro |
| Typical daily cost here | €1.02–1.18 at 3 g of dried | €0.65 at 2 capsules of 500 mg |
The Dose Problem Nobody Mentions
Reishi's best trial used 5.4 grams a day of a concentrated polysaccharide extract. A standard consumer regimen of two 500 mg capsules is 1 gram of extract — roughly a fifth of that, of a material that is not the same preparation.
Lion's mane has the opposite profile. Mori's 3 grams a day of dried fruiting body is reachable at ordinary cost with dried material, and our dosage guide covers how many capsules that actually means.
So the practical gap between trial and shelf is much wider for reishi than for lion's mane, which partly offsets reishi's advantage in trial size. Neither product is dishonest about it; nobody simply mentions it.
The Safety Difference That Decides Cases
In Poniedziałek's screen of eight edible mushroom species against human platelets, Ganoderma lucidum hot-water extract inhibited aggregation induced by both ADP and arachidonic acid, exceeding 140 µmol/L of aspirin on the ADP test, while leaving prothrombin time and INR unchanged. Hericium erinaceus showed no comparable effect.
For anyone taking aspirin, clopidogrel or an anticoagulant, or facing surgery, that is a one-directional argument for lion's mane regardless of which benefit they were originally after. Our articles on supplements before surgery and reishi interactions cover the detail.
Can You Take Both?
Nothing prevents it, and no trial has tested the combination. The reasonable case for stacking is that the endpoints do not overlap — cognition and fatigue — and the reasonable case against is that with two variables introduced at once you will never know which one did anything.
If you do combine them, the sensible sequence is one at a time for eight weeks each. Our stacking guide covers the general approach, and the cost of the disciplined version is only patience.
How to Choose
- Take an antiplatelet or anticoagulant, or have surgery booked? Lion's mane. This overrides everything below.
- Want the biggest single result in the category? Reishi. 132 patients, eight weeks, fatigue down 28.3% against 20.1% — the endpoint is fatigue, not sleep.
- Want cognitive support and are over 50? Lion's mane. Both of its longer trials recruited that population, which nothing else in the category did.
- Healthy, young, and after everyday sharpness? Expect little from either. The one healthy-adult trial found an acute speed effect and a stress result that missed significance.
- Buying reishi for sleep? Reconsider. There is no human randomised sleep trial — see our sleep supplement ranking.
- Match the dose to the trial you are buying. 3 g a day of dried lion's mane is reachable; reishi's 5.4 g of polysaccharide extract is not what a two-capsule regimen delivers.
- Budget for maintenance. Lion's mane's gains reversed four weeks after stopping, so this is an ongoing cost rather than a course.
The Honest Summary
Lion's mane is the better-studied of the two and the worse-studied in people like most buyers: its strong results come from adults with existing cognitive impairment, and its single healthy-adult trial produced one acute effect and one near-miss. Reishi is the less-studied of the two and holds the single most convincing result, in fatigue, at a dose far above what a standard capsule regimen supplies — while two of its three marketed uses, sleep and cardiovascular health, have either no human trial or a null Cochrane review.
If that sounds like a tie, the tiebreaker is not a benefit. It is that reishi carries a documented antiplatelet effect invisible to standard clotting tests and lion's mane does not, which settles the question for a large number of people before they get to comparing endpoints at all.
Frequently Asked Questions
Is lion's mane or reishi better for the brain?
Lion's mane, by evidence. It has two long trials in older adults with cognitive impairment and an acute processing-speed result in healthy young adults. Reishi has no cognitive trials; its best result is on fatigue.
Is reishi actually good for sleep?
There is no published randomised human sleep trial for reishi. The sleep story rests on preclinical work and on the fatigue and well-being results from a neurasthenia trial, which are related but not the same endpoint.
Can I take lion's mane and reishi together?
Nothing prevents it and no trial has studied the combination. Introducing them one at a time for eight weeks each is the only way to know which one produced any effect you notice.
Which is safer?
Lion's mane, on one specific and relevant point. In an eight-species platelet screen, reishi extract inhibited aggregation more strongly than aspirin on one test while leaving INR unchanged; lion's mane showed no comparable effect.
How long before either one does anything?
Reishi's fatigue trial ran eight weeks. Lion's mane showed significant cognitive change at week 8 and an acute processing-speed effect 60 minutes after a single dose. Neither is a one-week proposition for anything lasting.
Shop Lion's Mane and Reishi
Dried lion's mane (100 g €39, 500 g €169) is the cheapest route to Mori's 3 g daily dose at about €1 a day; capsules (120 caps €49) hold 0.5 g each. Reishi capsules (120 caps €39, 2 × 120 €70) are 500 mg each at two a day, and dried reishi (100 g €49) suits decoction. Compare across Focus & Cognition and Sleep & Relaxation. Free shipping on orders over €50.
Related Articles
- Best Mushrooms for Focus and Concentration
- Lion's Mane Dosage Guide
- Reishi Mushroom Dosage Guide
- Adaptogen vs Nootropic: Which Mushrooms Qualify
- Reishi and Sleep Quality
- Mushroom Supplement Stacking Guide
- Best Mushrooms for Stress and Cortisol
Sources
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-372. PubMed 18844328
- Li IC, Chang HH, Lin CH, et al. Prevention of early Alzheimer's disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Front Aging Neurosci. 2020;12:155. PubMed 32581767
- Docherty S, Doughty FL, Smith EF. The acute and chronic effects of lion's mane mushroom supplementation on cognitive function, stress and mood in young adults: a double-blind, parallel groups, pilot study. Nutrients. 2023;15(22):4842. PubMed 38004235
- Tang W, Gao Y, Chen G, et al. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. J Med Food. 2005;8(1):53-58. PubMed 15857210
- Klupp NL, Chang D, Hawke F, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2015;(2):CD007259. PubMed 25686270
- Poniedziałek B, Siwulski M, Wiater A, et al. The effect of mushroom extracts on human platelet and blood coagulation: in vitro screening of eight edible species. Nutrients. 2019;11(12):3040. PubMed 31842490
- Nagano M, Shimizu K, Kondo R, et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010;31(4):231-237. PubMed 20834180